Status:
COMPLETED
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
Lead Sponsor:
Exelixis
Conditions:
Glioblastoma
Giant Cell Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the highest safe dose of XL184 administered orally in combination with temozolomide (TMZ, Temodar®) and radiation therapy (RT). XL184 is a new chemical entity...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of Grade 4 astrocytic tumor, which includes glioblastoma, giant cell glioblastoma, gliosarcoma, and glioblastoma with oligodendroglial components.
- Must have had a partial or complete surgical resection of the Grade 4 astrocytic tumor.
- Subjects in Arm 1 must have had no previous treatment except surgery (ie, no previous RT, local chemotherapy, or systemic therapy). Subjects must meet certain other eligibility requirements.
- Subjects in Arm 2 must have completed a standard first line regimen of concurrent TMZ and RT for newly diagnosed GB, followed by a rest phase, and has not had any other previous treatment except surgery (including any other regimens of RT and local or systemic chemotherapy). Subjects must meet certain other eligibility requirements.
- Subjects must be able to undergo serial MRIs (computerized tomography \[CT\] may not substitute for magnetic resonance imaging \[MRI\]).
- Must be ≥ 18 years old.
- Must have a Karnofsky performance status of ≥ 70% and the ability to swallow whole capsules
- Must have no other diagnosis of malignancy (except surgically excised non-melanoma skin cancer or carcinoma in situ of the cervix, treated early stage prostate cancer, or a malignancy diagnosed ≥ 2 years previously with no current evidence of disease and no therapy within two years prior to enrollment on this study).
- Must be capable of understanding and complying with the protocol requirements and has signed the informed consent document.
- Sexually active fertile subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months after the last dose of study drug(s).
- Female subjects of childbearing potential must have a negative pregnancy test at screening.
Exclusion
- Subject has received prior systemic chemotherapy or RT (Arm 1) or prior systemic chemotherapy other than TMZ (Arm 2), biologic agents, or any other type of investigational agent for the treatment of brain tumors. Subjects who have progressed on TMZ are not eligible.
- Subject has evidence of acute intracranial or intratumoral hemorrhage \> Grade 1 either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin may enter the study.
- Subject has serious intercurrent illness such as: hypertension despite optimal treatment, or significant cardiac arrhythmias; or a recent history of serious disease such as symptomatic congestive heart failure, or abdominal fistula or gastrointestinal (GI) perforation within 6 months, prior to starting study treatment.
- Subject has had major surgery within 28 days prior to starting study treatment, or had non water-tight dural closure during previous surgery, or has unhealed wounds from previous surgery.
- Subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding.
- Subject is pregnant or breastfeeding.
- Subject is known to be positive for the human immunodeficiency virus (HIV) (a test for HIV at screening is not required).
- Subject has a previously-identified allergy or hypersensitivity to components of either the XL184 or TMZ formulations.
- Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00960492
Start Date
September 1 2009
End Date
October 1 2013
Last Update
September 22 2014
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
3
Henry Ford Health System
Detroit, Michigan, United States, 48202
4
Beth Israel Medical Center
New York, New York, United States, 10003